The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $785,892 in first-year total cost, median $392,946.
Most frequent study sections
- Special Emphasis Panel[ZRG1 IDM-V (12)]1
- Special Emphasis Panel[ZRG1 OTC-H (13)]1
Most frequent institutions
- DAKTARI DIAGNOSTICS, INC.1
- IMCARE BIOTECH, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2015 | A novel diagnostic biomarker for Hepatocellular Carcinoma(HCC)2R44CA165314-02A1 | LU, XUANYONG | IMCARE BIOTECH, INC., PA | $632,643 | ZRG1 |
| 2014 | Development of a Microfluidic Point-of-Care HCV Viral Load Assay1R44AI106215-01A1 | FERNANDEZ-SUAREZ, MARTA | DAKTARI DIAGNOSTICS, INC., MA | $153,249 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.